Contrast-enhanced high resolution MRI for atherosclerotic carotid artery tissue characterization

Contrast enhancement in atherosclerosis development in a mouse model: in vivo results at 2 Tesla

To develop an MRI method for the evaluation of contrast enhancement in early atherosclerotic plaque development in the abdominal aorta of a mouse model. Male apoE-/- mice from three groups, respectively 4 (n = 6), 8 (n = 11) and 16 (n = 4) weeks were included. Axial T1 spin echo images of the abdominal aorta were obtained above and below the renal arteries (90 microm spatial resolution) before and over 1 h after the injection of a macromolecular contrast agent. Signal enhancement was measured in the vessel wall and compared to histological features. Maximal arterial wall signal enhancement was obtained from 16 to 32 min post injection. During this time, the signal-to-noise ratio increased by a factor up to 1.7 in 16 week mice and 2.7 and 2.4 in 8 and 4 weeks mice, respectively. The enhancement of the arterial wall appeared less pronounced in the oldest mice, 16 weeks old, exhibiting more advanced lesions. Using a macromolecular gadolinium agent, contrast uptake in atherogenesis varies with lesion stage and may be related to vessel-wall permeability. Dynamic contrast-enhanced MRI may be useful to evaluate the atherosclerotic plaque activity in mice.

Differentiation of Intraplaque Versus Juxtaluminal Hemorrhage/Thrombus in Advanced Human Carotid Atherosclerotic Lesions by In Vivo Magnetic Resonance Imaging

Background— Intraplaque hemorrhage and juxtaluminal hemorrhage/thrombus may differ in cause and clinical implications. This study tested the hypothesis that MRI can distinguish between intraplaque hemorrhage and juxtaluminal hemorrhage/thrombus and investigated the association between hemorrhage and underlying lesion types.

Methods and Results— Twenty-six patients scheduled for carotid endarterectomy were imaged with a 1.5-T GE scanner by a multicontrast-weighted MRI technique. Hemorrhages were identified with previously established MRI criteria, and differentiations were made between intraplaque and juxtaluminal hemorrhage/thrombus. Corresponding histology was used to confirm the magnetic resonance findings. Tissues underlying areas of hemorrhage/thrombus were histologically categorized according to modified American Heart Association criteria. Of 190 matched sections, 140 contained areas of hemorrhage by histology, of which MRI correctly detected 134. The sensitivity and specificity for MRI to correctly identify cross sections that contained hemorrhage were 96% and 82%, respectively. Furthermore, MRI was able to distinguish juxtaluminal hemorrhage/thrombus from intraplaque hemorrhage with an accuracy of 96%. The distribution of lesion types underlying hemorrhages differed significantly ( P =0.004). Intraplaque hemorrhage had an underlying lipid-rich type IV/V lesion in 55% of histological sections, whereas juxtaluminal hemorrhage/thrombus had an underlying calcified lesion type VII in 70% of sections.

Conclusions— In vivo high-resolution MRI can detect and differentiate intraplaque hemorrhage from juxtaluminal hemorrhage/thrombus with good accuracy. The association of hemorrhage and lesion types suggests potential differences in origin. Noninvasive MRI therefore provides a possible tool for prospectively studying differences in origin of plaque hemorrhage and the association of plaque progression and instability.

Quantitative evaluation of carotid plaque composition by in vivo MRI

OBJECTIVE

This study evaluates the ability of MRI to quantify all major carotid atherosclerotic plaque components in vivo.

METHODS AND RESULTS

Thirty-one subjects scheduled for carotid endarterectomy were imaged with a 1.5T scanner using time-of-flight-, T1-, proton density-, and T2-weighted images. A total of 214 MR imaging locations were matched to corresponding histology sections. For MRI and histology, area measurements of the major plaque components such as lipid-rich/necrotic core (LR/NC), calcification, loose matrix, and dense (fibrous) tissue were recorded as percentages of the total wall area. Intraclass correlation coefficients (ICCs) were computed to determine intrareader and inter-reader reproducibility. MRI measurements of plaque composition were statistically equivalent to those of histology for the LR/NC (23.7 versus 20.3%; P=0.1), loose matrix (5.1 versus 6.3%; P=0.1), and dense (fibrous) tissue (66.3% versus 64%; P=0.4). Calcification differed significantly when measured as a percentage of wall area (9.4 versus 5%; P<0.001). Intrareader and inter-reader reproducibility was good to excellent for all tissue components, with ICCs ranging from 0.73 to 0.95.

CONCLUSIONS

MRI-based tissue quantification is accurate and reproducible. This application can be used in therapeutic clinical trials and in prospective longitudinal studies to examine carotid atherosclerotic plaque progression and regression.

Molecular, cellular and functional imaging of atherothrombosis

Recent years have seen a dramatic expansion in our knowledge of the events of atherogenesis and in the availability of drugs that can retard the progression - and even induce the regression - of this disease process. Our understanding has been advanced considerably by developments in genetics and molecular biology and by the use of genetically modified mouse models that have provided key mechanistic insights. Increasingly sophisticated imaging techniques will capitalize on these advances by bringing forward diagnosis, enhancing disease characterization and providing more precise evaluation of the effects of treatment. In this review, techniques for imaging atherosclerosis and thrombosis will be discussed. Particular attention will be given to magnetic resonance imaging techniques that enable lesion characterization and allow the targeted imaging of cells, molecules and biological processes. Emphasis is given to the potential contribution of magnetic resonance imaging methods to therapeutic monitoring, drug delivery and drug discovery.

MRI of atherosclerosis

The emergence of high-resolution, rapid imaging methods has enabled MRI to noninvasively image the fine internal structure of atherosclerotic artery walls. This capability has, in turn, captured the interest of clinicians, who see it as an opportunity to assess disease severity based on the characteristics of atherosclerotic lesions themselves, rather than only their effects on the vessel lumen. MRI of atherosclerosis thus has the potential to be used in medical treatment decisions or to assess the effects of experimental treatment options. Given this potential, a number of research groups have been investigating MRI of atherosclerosis in an effort to establish the ability of MRI to determine atherosclerotic plaque burden, detect plaque composition, and ultimately identify vulnerable plaque before it leads to a clinical event. In this review, the current state of the art is summarized for the three primary vessel targets: the carotid artery, the aorta, and the coronary arteries.

Imaging of high-risk plaque

'High-risk' or 'vulnerable' plaques in the coronary arteries have characteristics that make them more prone to disruption and subsequent thrombosis -- the mechanisms of most acute coronary syndromes (ACS). There are a number of imaging modalities that are capable of visualizing these features. This article discusses invasive modalities for identifying 'high-risk' plaque such as intravascular ultrasound, coronary angioscopy, optical coherence tomography, near-infrared spectroscopy and coronary thermography. It also discusses the use of noninvasive modalities such as computed tomography MRI and ultrasound. When these imaging modalities are combined with standard cardiac risk factors and more novel markers of systemic inflammation and thrombogenicity we can improve our ability to identify the 'high-risk' patient.

Magnetic resonance imaging and computed tomography in assessment of atherosclerotic plaque

The two most promising noninvasive imaging modalities for the study of atherosclerosis are magnetic resonance imaging (MRI) and computed tomography (CT). Both have been shown to be capable of imaging vessel wall structures and differentiating various stages of atherosclerotic wall changes. MRI has been applied in various in vivo human studies to image atherosclerotic plaques in coronary arteries, carotid arteries, and aorta. The latest generation of multidetector row computed tomography (MDCT) systems allows for the noninvasive characterization of different plaque components in various vascular structures. MDCT allows evaluation of the whole arterial vasculature. In addition, MDCT has the ability to visualize the vessel wall and to give a quantitative measurement of calcified and noncalcified plaque. Using either technique, the repeatable, noninvasive study of atherosclerotic disease during its natural history and after therapeutic intervention will enhance our understanding of disease progression and regression. MDCT and MRI, therefore, may help in selecting appropriate treatments.

Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging

BACKGROUND

MRI of specific components in atherosclerotic plaque may provide information on plaque stability and its potential to rupture. We evaluated gadofluorine in atherosclerotic rabbits using a new MR sequence that allows plaque detection within 1 hour after injection and assessed enhancement in lipid-rich and non-lipid-rich plaques.

METHODS AND RESULTS

Twelve rabbits with aortic plaque and 6 controls underwent MRI before and up to 24 hours after gadofluorine injection (50 micromol/kg). Two T1-weighted, segmented gradient-echo sequences (TFL) were compared to enhance vessel wall delineation after injection: (1) an inversion-recovery prepulse (IR-TFL) or (2) a combination of inversion-recovery and diffusion-based flow suppression prepulses (IR-DIFF-TFL). With the use of IR-TFL at 1 hour after injection, the vessel wall was not delineated because of poor flow suppression; at 24 hours after injection, the enhancement was 37% (P<0.01). IR-DIFF-TFL showed significant enhancement after versus before contrast (1 hour: 164% [P<0.005]; 24 hours: 207% [P<0.001]). At 1 hour and 24 hours after injection, the contrast-to-noise ratio was higher with the use of IR-DIFF-TFL than with IR-TFL (1 hour: 13.0+/-7.7 versus -19.8+/-10.3 [P<0.001]; 24 hours: 15.2+/-5.9 versus 11.4+/-8.9, respectively [P=0.052]). There was no enhancement in the vessel wall after gadofluorine injection in the control group. A strong correlation was found (r2=0.87; P<0.001) between the lipid-rich areas in histological sections and signal intensity in corresponding MR images. This suggests a high affinity of gadofluorine for lipid-rich plaques.

CONCLUSIONS

Gadofluorine-enhanced MRI improves atherosclerotic plaque detection. The IR-DIFF-TFL method allows early detection of atherosclerotic plaque within 1 hour after gadofluorine injection.

Segmentation of wall and plaque in in vitro vascular MR images

Atherosclerosis leads to heart attack and stroke, which are major killers in the western world. These cardiovascular events frequently result from local rupture of vulnerable atherosclerotic plaque. Non-invasive assessment of plaque vulnerability would dramatically change the way in which atherosclerotic disease is diagnosed, monitored, and treated. In this paper, we report a computerized method for segmentation of arterial wall layers and plaque from high-resolution volumetric MR images. The method uses dynamic programming to detect optimal borders in each MRI frame. The accuracy of the results was tested in 62 T1-weighted MR images from six vessel specimens in comparison to borders manually determined by an expert observer. The mean signed border positioning errors for the lumen, internal elastic lamina, and external elastic lamina borders were -0.1 +/- 0.1, 0.0 +/- 0.1, and -0.1 +/- 0.1 mm, respectively. The presented wall layer segmentation approach is one of the first steps towards non-invasive assessment of plaque vulnerability in atherosclerotic subjects.

Micro-CT of Carotid Arteries: A Tool for Experimental Studies

Micro-computed tomography (micro-CT) is a high-resolution, non-destructive tool for two- and three-dimensional imaging and quantification. The ability of this technique to assess atherosclerosis of the carotid artery was evaluated in three human cadaver samples based on the original axial acquisitions, multiplanar reconstructions and volume rendering techniques. Quantitative analysis included the calculation of: (1) the original lumen perimeter, original lumen area, plaque area, residual lumen area, calcified area and gross sectional area reduction of the vascular lumen from two-dimensional slices; (2) the total tissue volume, soft tissue volume and calcified tissue volume from the three-dimensional data set. This preliminary study demonstrates the potential of micro-CT as a supplementary method for the two- and three-dimensional ex vivo evaluation of carotid atherosclerosis.

Evaluation of carotid stenosis with axial high-resolution black-blood MR imaging

High-resolution axial black-blood MR imaging (BB MRI) has been shown to be able to characterise carotid plaque morphology. The aim of this study was to explore the accuracy of this technique in quantifying the severity of carotid stenosis. A prospective study of 54 patients with symptomatic carotid disease was conducted, comparing BB MRI to the gold standard, conventional digital subtraction X-ray angiography (DSA). The BB MRI sequence was a fast-spin echo acquisition (TE = 42 ms, ETL = 24, field of view = 100 x 100 mm, slice thickness = 3.0 mm) at 1.5 T using a custom-built phased-array coil. Linear measurements of luminal and outer carotid wall diameter were made directly from the axial BB MRI slices by three independent blinded readers and stenosis was calculated according to European Carotid Surgery Trial (ECST) criteria. There was good agreement between BB MRI and DSA (intraclass correlation = 0.83). Inter-observer agreement was good (average kappa = 0.77). BB MRI was accurate for detection of severe stenosis (> or = 80%) with sensitivity and specificity of 87 and 81%, respectively. Eight cases of "DSA-defined" moderate stenosis were overestimated as severe by BB MRI and this may be related to non-circular lumens. Axial imaging with BB MRI could potentially be used to provide useful information about severity of carotid stenosis.

Magnetic resonance imaging identifies the fibrous cap in atherosclerotic abdominal aortic aneurysm

BACKGROUND

MRI can distinguish components of atherosclerotic plaque. We hypothesized that contrast enhancement with gadolinium-DTPA (Gd-DTPA) could aid in the differentiation of plaque components in abdominal aortic aneurysm (AAA).

METHODS AND RESULTS

Twenty-three patients (19 males, age 70+/-8 years) with AAA underwent MRI on a 1.5-T clinical scanner 3+/-3 days before surgical grafting. T1- and T2-weighted (W) black blood spin echo imaging was performed in 1 axial slice, and the T1-W imaging was repeated after a Gd-DTPA-enhanced 3D magnetic resonance angiogram. A section of the aorta at the site of imaging was resected at surgery for histopathologic examination of tissue components and inflammatory cells. Signal-to-noise and contrast-to-noise ratios (CNR) were measured in visualized plaque components from multispectral MRI, and percent enhancement after contrast on T1-W imaging was calculated. The kappa value for agreement between pathology and MRI for the number of tissue components was 0.785. T2-W imaging identified thrombus as regions of high signal and lipid core as low signal, with a CNR of 6.43+/-3.41. Nine patients had a fibrous cap pathologically, which was visualized as a discrete area of uniform increased signal on T2-W imaging with a CNR of 4.52+/-1.93 compared with lipid core. Within the cap, the percent enhancement after Gd-DTPA on T1-W imaging was 91+/-63%.

CONCLUSIONS

Higher signal on T2-W MRI identifies the fibrous cap and thrombus within AAA. Contrast enhancement improves delineation of the fibrous cap. The addition of contrast to MRI plaque imaging may enhance identification of vulnerable plaque.

Complementary results of computed tomography and magnetic resonance imaging of the heart and coronary arteries: a review and future outlook

MR and CT imaging are emerging as promising complementary imaging modalities in the primary diagnosis of CAD and for the detection of subclinical atherosclerotic disease. For the detection or exclusion of significant CAD, both cardiac CT (including coronary calcium screening and non-invasive coronary angiography), and cardiac MRI (using stress function and stress perfusion imaging) are becoming widely available for routine clinical evaluation. Their high negative predictive value, especially when combining two or more of these modalities, allows the exclusion of significant CAD with high certainty, provided that patients are selected appropriately. The primary goal of current investigations using this combined imaging approach is to reduce the number of unnecessary diagnostic coronary catheterizations, and not to replace cardiac catheterization altogether. For the diagnosis of obstructive coronary atherosclerosis and for screening for subclinical disease, CT and MRI have shown potential to directly image the atherosclerotic lesion, measure atherosclerotic burden, and characterize the plaque components. The information obtained may be used to assess progression and regression of atherosclerosis and may open new areas for diagnosis, prevention, and treatment of coronary atherosclerosis. Further clinical investigation is needed to define the technical requirements for optimal imaging, develop accurate quantitative image analysis techniques, outline criteria for image interpretation, and define the clinical indications for both MR or CT imaging. Additional studies are also needed to address the cost effectiveness of such a combined approach versus other currently available imaging modalities.

From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I

Atherosclerotic cardiovascular disease results in >19 million deaths annually, and coronary heart disease accounts for the majority of this toll. Despite major advances in treatment of coronary heart disease patients, a large number of victims of the disease who are apparently healthy die suddenly without prior symptoms. Available screening and diagnostic methods are insufficient to identify the victims before the event occurs. The recognition of the role of the vulnerable plaque has opened new avenues of opportunity in the field of cardiovascular medicine. This consensus document concludes the following. (1) Rupture-prone plaques are not the only vulnerable plaques. All types of atherosclerotic plaques with high likelihood of thrombotic complications and rapid progression should be considered as vulnerable plaques. We propose a classification for clinical as well as pathological evaluation of vulnerable plaques. (2) Vulnerable plaques are not the only culprit factors for the development of acute coronary syndromes, myocardial infarction, and sudden cardiac death. Vulnerable blood (prone to thrombosis) and vulnerable myocardium (prone to fatal arrhythmia) play an important role in the outcome. Therefore, the term "vulnerable patient" may be more appropriate and is proposed now for the identification of subjects with high likelihood of developing cardiac events in the near future. (3) A quantitative method for cumulative risk assessment of vulnerable patients needs to be developed that may include variables based on plaque, blood, and myocardial vulnerability. In Part I of this consensus document, we cover the new definition of vulnerable plaque and its relationship with vulnerable patients. Part II of this consensus document focuses on vulnerable blood and vulnerable myocardium and provide an outline of overall risk assessment of vulnerable patients. Parts I and II are meant to provide a general consensus and overviews the new field of vulnerable patient. Recently developed assays (eg, C-reactive protein), imaging techniques (eg, CT and MRI), noninvasive electrophysiological tests (for vulnerable myocardium), and emerging catheters (to localize and characterize vulnerable plaque) in combination with future genomic and proteomic techniques will guide us in the search for vulnerable patients. It will also lead to the development and deployment of new therapies and ultimately to reduce the incidence of acute coronary syndromes and sudden cardiac death. We encourage healthcare policy makers to promote translational research for screening and treatment of vulnerable patients.

Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles

BACKGROUND

Angiogenesis is a critical feature of plaque development in atherosclerosis and might play a key role in both the initiation and later rupture of plaques that lead to myocardial infarction and stroke. The precursory molecular or cellular events that initiate plaque growth and that ultimately contribute to plaque instability, however, cannot be detected directly with any current diagnostic modality.

METHODS AND RESULTS

Atherosclerosis was induced in New Zealand White rabbits fed 1% cholesterol for approximately 80 days. alpha(v)beta3-Integrin-targeted, paramagnetic nanoparticles were injected intravenously and provided specific detection of the neovasculature within 2 hours by routine magnetic resonance imaging (MRI) at a clinically relevant field strength (1.5 T). Increased angiogenesis was detected as a 47+/-5% enhancement in MRI signal averaged throughout the abdominal aortic wall among rabbits that received alpha(v)beta3-targeted, paramagnetic nanoparticles. Pretreatment of atherosclerotic rabbits with alpha(v)beta3-targeted, nonparamagnetic nanoparticles competitively blocked specific contrast enhancement of the alpha(v)beta3-targeted paramagnetic agent. MRI revealed a pattern of increased alpha(v)beta3-integrin distribution within the atherosclerotic wall that was spatially heterogeneous along both transverse and longitudinal planes of the abdominal aorta. Histology and immunohistochemistry confirmed marked proliferation of angiogenic vessels within the aortic adventitia, coincident with prominent, neointimal proliferation among cholesterol-fed, atherosclerotic rabbits in comparison with sparse incidence of neovasculature in the control animals.

CONCLUSIONS

This molecular imaging approach might provide a method for defining the burden and evolution of atherosclerosis in susceptible individuals as well as responsiveness of individual patients to antiatherosclerotic therapies.

High-resolution magnetic resonance imaging at 2 Tesla: potential for atherosclerotic lesions exploration in the apolipoprotein E knockout mouse

INTRODUCTION

The aim of the present study was to evaluate the potential of high-resolution MRI at 2 Tesla (T) for direct noninvasive imaging of the aortic wall in a mouse model of atherosclerosis.

MATERIAL AND METHODS

A specific mouse antenna was developed and sequence parameters were adjusted. T(1)- and T2-weighted images of abdominal aorta were obtained at 2 T with a spatial resolution of 86 x 86 x 800 microm3 in vivo. With a dedicated small coil, ex vivo MRI of the aorta was performed with a spatial resolution of 54 x 54 x 520 microm3.

RESULTS

In vivo, the aortic wall was clearly defined on T(2)-weighted images in 15 of 16 mice: along the aorta the lumen circumference ranged from 1.07 to 3.61 mm and mean wall thickness from 0.11 to 0.67 mm. In vivo measurements of plaque distribution were confirmed by ex vivo MR imaging and by histology, with a good correlation with histology regarding lumen circumference (r = 0.94) and wall thickness (r = 0.97).

CONCLUSION

Magnetic resonance imaging at 2 T to analyze in vivo atherosclerotic lesions in mice is possible with a spatial resolution of 86 x 86 x 800 microm3 and thus can be used for noninvasive follow-up in evaluation of new drugs.

Measurement of carotid wall volume and maximum area with contrast-enhanced 3D MR imaging: initial observations

PURPOSE

To investigate whether postcontrast three-dimensional (3D) magnetic resonance (MR) imaging would yield more accurate measurement of carotid artery wall volume and maximum wall area, which are both measures of plaque burden, than precontrast 3D MR imaging.

MATERIALS AND METHODS

Eleven consecutive patients scheduled to undergo carotid endarterectomy were recruited for the study. A 3D fast gradient-recalled-echo sequence was applied to acquire both precontrast and postcontrast images of the carotid artery wall. The same sequence was used to image the ex vivo excised plaque as a reference for measurement of carotid wall volume and maximum wall area.

RESULTS

The mean difference in maximum wall area between the precontrast in vivo measurements and the ex vivo measurements (mean +/- SD, 18.22 mm2 +/- 15.61) was significantly larger than that between the postcontrast in vivo measurements and the ex vivo measurements (12.33 mm2 +/- 14.49) (P =.02). The difference in wall volume between the precontrast in vivo measurements and the ex vivo measurements (41.81 mm3 +/- 36.51) was larger than that between the postcontrast in vivo measurements and the ex vivo measurements (32.73 mm3 +/- 35.00) (P =.004). Postcontrast images yielded better correlation with ex vivo images than did precontrast images, in both carotid luminal area (R = 0.88 for postcontrast images, R = 0.80 for precontrast images) and outer wall boundary area (R = 0.79 for postcontrast images, R = 0.71 for precontrast images) measurements.

CONCLUSION

Postcontrast 3D MR imaging may be useful in the measurement of carotid artery plaque burden.

The impact of spatial resolution and respiratory motion on MR imaging of atherosclerotic plaque

PURPOSE

To examine the impact of spatial resolution and respiratory motion on the ability to accurately measure atherosclerotic plaque burden and to visually identify atherosclerotic plaque composition.

MATERIALS AND METHODS

Numerical simulations of the Bloch equations and vessel wall phantom studies were performed for different spatial resolutions by incrementally increasing the field of view. In addition, respiratory motion was simulated based on a measured physiologic breathing pattern.

RESULTS

While a spatial resolution of > or = 6 pixels across the wall does not result in significant errors, a resolution of < or = 4 pixels across the wall leads to an overestimation of > 20%. Using a double-inversion T2-weighted turbo spin echo sequence, a resolution of 1 pixel across equally thick tissue layers (fibrous cap, lipid, smooth muscle) and a respiratory motion correction precision (gating window) of three times the thickness of the tissue layer allow for characterization of the different coronary wall components.

CONCLUSIONS

We found that measurements in low-resolution black blood images tend to overestimate vessel wall area and underestimate lumen area.

Tissue-specific MR contrast agents

The purpose of this review is to outline recent trends in contrast agent development for magnetic resonance imaging. Up to now, small molecular weight gadolinium chelates are the workhorse in contrast enhanced MRI. These first generation MR contrast agents distribute into the intravascular and interstitial space, thus allowing the evaluation of physiological parameters, such as the status or existence of the blood-brain-barrier or the renal function. Shortly after the first clinical use of paramagnetic metallochelates in 1983, compounds were suggested for liver imaging and enhancing a cardiac infarct. Meanwhile, liver specific contrast agents based on gadolinium, manganese or iron become reality. Dedicated blood pool agents will be available within the next years. These gadolinium or iron agents will be beneficial for longer lasting MRA procedures, such as cardiac imaging. Contrast enhanced lymphography after interstitial or intravenous injection will be another major step forward in diagnostic imaging. Metastatic involvement will be seen either after the injection of ultrasmall superparamagnetic iron oxides or dedicated gadolinium chelates. The accumulation of both compound classes is triggered by an uptake into macrophages. It is likely that similar agents will augment MRI of atheriosclerotic plaques, a systemic inflammatory disease of the arterial wall. Thrombus-specific agents based on small gadolinium labeled peptides are on the horizon. It is very obvious that the future of cardiovascular MRI will benefit from the development of new paramagnetic and superparamagnetic substances. The expectations for new tumor-, pathology- or receptor-specific agents are high. However, is not likely that such a compound will be available for daily routine MRI within the next decade.

Vascular MRI in the diagnosis and therapy of the high risk atherosclerotic plaque

Disruption of a high risk plaque is known as the primary cause of cardiovascular events. Characterization of arterial wall components has become an essential adjunct in the identification of patients with plaques prone to rupture. Magnetic Resonance Imaging (MRI) has been revealed as one of the noninvasive tools possibly capable of identifying and characterizing high risk atherosclerotic plaque. MRI may facilitate diagnosis, and guide and serially monitor interventional and pharmacological treatment of atherosclerotic disease. In addition, it permits the simultaneous assessment of the anatomy, morphology, and hemodynamics for the study of flow-induced atherogenesis. It possibly will identify asymptomatic patients with subclinical atherosclerosis. This has potential significance for the improvement of strategies in primary and secondary prevention.

New balloon-thermography catheter for in vivo temperature measurements in human coronary atherosclerotic plaques: a novel approach for thermography?

Although ex vivo studies showed marked thermal heterogeneity in atheromatic plaques, in in vivo human studies trivial temperature variations are recorded due to the cooling effect of blood flow. We investigated a new balloon-thermogaphy catheter for temperature measurements during coronary flow interruption. A thermistor probe is positioned at the distal segment of the catheter. At the opposite site of the thermistor, a balloon is placed. By inflation of the balloon, coronary flow is interrupted. Ten patients with effort angina were studied. Coronary flow velocity was continuously recorded. Temperature was recorded at the proximal vessel wall and at the lesion before, during, and after complete interruption of blood flow by inflation of the balloon. DeltaTp was assigned as the difference between the background temperature and the maximal temperature during and after balloon inflation. DeltaTl was assigned as the difference between the atherosclerotic plaque and the proximal vessel wall. The procedure was not complicated. DeltaTp during and after balloon inflation was 0.01 +/- 0.01 degrees C and -0.003 +/- -0.01 degrees C (P < 0.001), respectively. DeltaTl was 0.07 +/- 0.04 degrees C at baseline, 0.17 +/- 0.06 degrees C (59.3% +/- 11.8% increase) during, and 0.07 +/- 0.05 degrees C after flow interruption (P < 0.001). DeltaTl was greater than DeltaTp during and after impairment of flow (P < 0.001). In vivo atherosclerotic plaque temperature recording seems to be feasible with this new balloon-thermography catheter. This device may introduce a new approach for the detection of thermal heterogeneity in plaques by addressing the issue of cooling effect of blood flow.

Quantitative magnetic resonance imaging analysis of neovasculature volume in carotid atherosclerotic plaque

BACKGROUND

Neovasculature within atherosclerotic plaques is believed to be associated with infiltration of inflammatory cells and plaque destabilization. The aim of the present investigation was to determine whether the amount of neovasculature present in advanced carotid plaques can be noninvasively measured by dynamic, contrast-enhanced MRI.

METHODS AND RESULTS

A total of 20 consecutive patients scheduled for carotid endarterectomy were recruited to participate in an MRI study. Images were obtained at 15-second intervals, and a gadolinium contrast agent was injected coincident with the second of 10 images in the sequence. The resulting image intensity within the plaque was tracked over time, and a kinetic model was used to estimate the fractional blood volume. For validation, matched sections from subsequent endarterectomy were stained with ULEX and CD-31 antibody to highlight microvessels. Finally, all microvessels within the matched sections were identified, and their total area was computed as a fraction of the plaque area. Results were obtained from 16 participants, which showed fractional blood volumes ranging from 2% to 41%. These levels were significantly higher than the histological measurements of fractional vascular area. Nevertheless, the 2 measurements were highly correlated, with a correlation coefficient of 0.80 (P<0.001).

CONCLUSIONS

Dynamic contrast-enhanced MRI provides an indication of the extent of neovasculature within carotid atherosclerotic plaque. MRI therefore provides a means for prospectively studying the link between neovasculature and plaque vulnerability.

MR imaging for the noninvasive assessment of atherothrombotic plaques

Imaging methods to quantify the progression and regression of atherosclerosis could play a strong role in the management of patients. High-resolution, noninvasive MR imaging may provide exhaustive 3D anatomical information about the lumen and the vessel wall. Furthermore, MR imaging has the ability to characterize plaque composition and microanatomy and therefore to identify lesions vulnerable to rupture or erosion. The high resolution of MR imaging and the development of sophisticated contrast agents offer the promise of molecular in vivo molecular imaging of the plaque. This may aid early intervention (eg, lipid-lowering drug regiments) in both primary and secondary treatment of vascular disease in all arterial beds.

T1-insensitive flow suppression using quadruple inversion-recovery

A new flow suppression method has been proposed for the acquisition of blood-suppressed (black-blood) images in combination with administration of a positive contrast agent. The technique employs the quadruple inversion-recovery (QIR) preparative pulse sequence, which consists of two double-inversion modules followed by two delays. Within each double inversion, a nonselective RF pulse is immediately followed by a slice-selective one. The time intervals of the sequence can be calculated using an algorithm based on minimization of the variation of a signal equation over an entire range of T(1) occurring in blood before and after contrast administration. QIR is highly insensitive to variations of T(1), providing efficient suppression of a flow signal with T(1) in a range of 200-1200 ms. The technique utilizes identical scan parameters for pre- and postcontrast acquisition, and thus allows reliable quantitative interpretation of contrast enhancement (CE). The clinical application of QIR was demonstrated in high-resolution, contrast-enhanced, black-blood imaging of atherosclerotic plzzaque.

Vulnerable atherosclerotic plaque: emerging challenge for animal models

A recent shift in the clinical paradigm of acute coronary syndromes led to a burst of activity in developing animal models related to plaque vulnerability. In the present review, animal models of spontaneous and induced plaque rupture, thrombosis, and hemorrhage and "vulnerability endpoints" in conventional models of atherosclerosis are discussed. These endpoints include readouts related to biomechanical properties of the plaques, collagen turnover, underlying inflammation, and lipid accumulation. Challenges in model validation are emphasized. Development of new animal models and new tools of monitoring plaque vulnerability will facilitate design of plaque-stabilizing therapies.

Classification of human carotid atherosclerotic lesions with in vivo multicontrast magnetic resonance imaging

BACKGROUND

Recent studies demonstrated that in vivo and ex vivo MRI can characterize the components of the carotid atherosclerotic plaque, such as fibrous tissue, lipid/necrotic core, calcium, hemorrhage, and thrombus. The purpose of this study was to determine whether in vivo high-resolution multicontrast MRI could accurately classify human carotid atherosclerotic plaque according to the American Heart Association classification.

METHODS AND RESULTS

Sixty consecutive patients (mean age 70 years; 54 males) scheduled for carotid endarterectomy were imaged with a 1.5-T scanner after informed consent was obtained. A standardized protocol was used to obtain 4 different contrast-weighted images (time of flight and T1-, PD-, and T2-weighted) of the carotid arteries. Best voxel size was 0.25x0.25x1 mm3. Carotid plaques were removed intact and processed for histological examination. Both MR images and histological sections were independently reviewed, categorized, and compared. Overall, the classification obtained by MRI and the American Heart Association classifications showed good agreement, with Cohen's kappa (95% CI) of 0.74 (0.67 to 0.82) and weighted kappa of 0.79. The sensitivity and specificity, respectively, of MRI classification were as follows: type I-II lesions, 67% and 100%; type III lesions, 81% and 98%; type IV-V lesions, 84% and 90%; type VI lesions, 82% and 91%; type VII lesions, 80% and 94%; and type VIII lesions, 56% and 100%.

CONCLUSIONS

In vivo high-resolution multicontrast MRI is capable of classifying intermediate to advanced atherosclerotic lesions in the human carotid artery and is also capable of distinguishing advanced lesions from early and intermediate atherosclerotic plaque.

Quantitative evaluation of carotid atherosclerotic plaques by magnetic resonance imaging

In order to study human atherosclerotic plaque burden and composition in vivo, an imaging technique is needed that can directly measure volume and characterize the cross-sectional morphologic components of the atherosclerotic arterial wall. High-resolution magnetic resonance imaging (MRI), which is noninvasive and nonirradiative, has been described as one promising modality to achieve these purposes. MRI allows direct visualization of the diseased vessel wall and is capable of characterizing the morphology of individual atherosclerotic carotid plaques.

Carotid atherosclerotic wall imaging by MRI

High spatial resolution magnetic resonance imaging (MRI) is one of the most promising modalities for visualizing the carotid atherosclerotic plaque. MR allows direct visualization of the diseased vessel wall, is capable of characterizing plaque morphology, and can potentially monitor progression of the disease. Though ultrasound and angiography have been the principal methods for determining the severity of carotid atherosclerosis and the need for endarterectomy, these methods only measure percentage of vessel stenosis. There is strong evidence that this is not the best indicator for assessing clinical risk. Improved imaging techniques are therefore needed to reliably identify the high-risk plaques that lead to cerebrovascular events. This article focuses on the current state-of-the-art in MR carotid atherosclerotic plaque imaging to evaluate plaque morphology and composition.

Noncoronary and coronary atherothrombotic plaque imaging and monitoring of therapy by MRI

In the future, the use of imaging methods to quantify the progression and regression of atherosclerosis could play a strong role in the management of patients. High-resolution, noninvasive MRI may provide exhaustive 3-D anatomic information about the lumen and the vessel wall. Furthermore, MRI has the ability to characterize plaque composition and microanatomy and therefore to identify lesions vulnerable to rupture or erosion. The high resolution of MRI and the development of sophisticated contrast agents offer the promise of molecular in vivo molecular imaging of the plaque. This may aid early intervention (e.g., lipid lowering drug regiments) in both primary and secondary treatment of vascular disease in all arterial beds.

MRI and characterization of atherosclerotic plaque: emerging applications and molecular imaging

Noninvasive high-resolution magnetic resonance has the potential to image atherosclerotic plaque and to determine its composition and microanatomy. This review summarizes the rationale for plaque imaging and describes the characteristics of plaque by use of existing MRI techniques. The use of MRI in human disease and in animal models, particularly in rabbits and mice, is presented. Present and future applications of MRI, including real-time vascular intervention, new contrast agents, and molecular imaging, are also discussed.

Noise and motion correction in dynamic contrast-enhanced MRI for analysis of atherosclerotic lesions

Dynamic contrast-enhanced MRI of atherosclerotic vessels after contrast agent injection may provide unique information regarding lesion structure and vulnerability. The high-resolution images necessary for viewing lesion substructures, however, are often corrupted by patient motion and low signal-to-noise ratios, making pixel-level analyses difficult. This article presents a postprocessing method that enables pixel-level analysis of dynamic images by eliminating motion and enhancing image quality. Noise and motion correction are performed using optimal statistical methods under the assumption that noise and contrast agent dynamics are random processes. The method is demonstrated and validated on dynamic images of atherosclerotic plaques in human carotid arteries.

Non-invasive imaging of plaque vulnerability: an important tool for the assessment of agents to stabilise atherosclerotic plaques

Disruption of a vulnerable atherosclerotic plaque is well-recognised as the primary cause of stroke, non-fatal myocardial infarction and sudden cardiac death. Novel therapeutic agents are being developed to stabilise such plaques. The initial evaluation of these drugs would be facilitated by the use of non-invasive imaging techniques to identify vulnerable plaque and document serial changes in plaque stability. The aim of this review is to explain the characteristics of the leading non-invasive imaging modalities and discuss their role in examining the vulnerable plaque. This knowledge will be extremely important for physicians and scientists involved in the clinical evaluation of novel agents to stabilise the vulnerable plaque.